Evidence map›Paper›PMID 35631364›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Design, Synthesis and Evaluation of Fused Bicyclo[2.2.2]octene as a Potential Core Scaffold for the Non-Covalent Inhibitors of SARS-CoV-2 3CL

Barbara Herlah, Andrej Hoivik, Luka Jamšek, Katja Valjavec, Norio Yamamoto, Tyuji Hoshino, Krištof Kranjc, Andrej Perdih

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Triphenylmethyl Group as a Highly DiastereoselectiveMolecules (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Barbara HerlahNational Institute of Chemistry, Hajdrihova ulica 19, SI-1000 Ljubljana, Slovenia.ORCID 0000-0002-5585-2396
Andrej HoivikFaculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, SI-1000 Ljubljana, Slovenia.ORCID 0000-0002-0357-1875
Luka JamšekFaculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, SI-1000 Ljubljana, Slovenia.
Katja ValjavecNational Institute of Chemistry, Hajdrihova ulica 19, SI-1000 Ljubljana, Slovenia.
Norio YamamotoDepartment of Microbiology, Tokai University School of Medicine, 143 Shimokasuya, Isehara 259-1193, Kanagawa, Japan.
Tyuji HoshinoGraduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Chiba, Japan.ORCID 0000-0003-4705-4412
Krištof KranjcFaculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, SI-1000 Ljubljana, Slovenia.
Andrej PerdihNational Institute of Chemistry, Hajdrihova ulica 19, SI-1000 Ljubljana, Slovenia.ORCID 0000-0002-6645-9231
University of Ljubljana · SIChiba University · JPNational Institute of Chemistry · SITokai University · JP

Funding

Slovenian Research Agency P1-0012Slovenian Research Agency P1-0230-0103
6 · The paper itself

Abstract

The emergence of SARS-CoV-2, responsible for the global COVID-19 pandemic, requires the rapid development of novel antiviral drugs that would contribute to an effective treatment alongside vaccines. Drug repurposing and development of new molecules targeting numerous viral targets have already led to promising drug candidates. To this end, versatile molecular scaffolds with high functionalization capabilities play a key role. Starting with the clinically used conformationally flexible HIV-1 protease inhibitors that inhibit replication of SARS-CoV-2 and bind major protease 3CL

Indexed as

3CLpro main proteasebicyclo[2.2.2]octenesCOVID-19 antiviral drugsmolecular scaffoldsSARS-CoV-2

Identifiers

PMID35631364
PMCPMC9145702
OpenAlexW4224987945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.